pthrp

Abaloparatide Reduces Osteoporotic Spine Fractures by 84%

Abaloparatide, an analog of human PTHrP (1-34), shows strong potential in treating osteoporosis by boosting bone formation while limiting resorption. Animal studies confirm its ability to reverse bone loss in ovariectomy models, and a phase 3 trial revealed an 84% lower risk of new spine fractures at 43 months compared to placebo. This peptide offers advantages over traditional antiresorptives by improving bone strength and density.